Bisbibenzyls, novel proteasome inhibitors, suppress androgen receptor transcriptional activity and expression accompanied by activation of autophagy in prostate cancer LNCaP cells

References

• Adams J. (2004). The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417–21
   PubMed Web of Science ®Google Scholar
• Bluemn EG, Nelson PS. (2012). The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 24:251–7
   PubMed Web of Science ®Google Scholar
• Boutin B, Tajeddine N, Vandersmissen P, et al. (2013). Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis. The Prostate 73:1090–102
   PubMed Web of Science ®Google Scholar
• Chen D, Cui Q-C, Yang H, et al. (2007). Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 67:1636–44
   PubMed Web of Science ®Google Scholar
• Chymkowitch P, Le-May N, Charneau P, et al. (2011). The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J 30:468–79
   PubMed Web of Science ®Google Scholar
• Davis JN, Wojno KJ, Daignault S, et al. (2006). Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 66:11897–906
   PubMed Web of Science ®Google Scholar
• Ding WX, Ni HM, Gao W, et al. (2007). Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 171:513–24
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Feldman D. (2011). The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45
   Web of Science ®Google Scholar
• Guseva NV, Rokhlin OW, Glover RA, Cohen MB. (2012). P53 and the proteasome regulate androgen receptor activity. Cancer Biol Ther 13:553–8
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. (2002). Androgen receptor (AR) coregulators: An overview. Endocr Rev 23:175–200
   PubMed Web of Science ®Google Scholar
• Huang H, Zegarra-Moro OL, Benson D, Tindall DJ. (2004). Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene 23:2161–76
   PubMed Web of Science ®Google Scholar
• Jaworski T. (2006). Degradation and beyond: Control of androgen receptor activity by the proteasome system. Cell Mol Biol Lett 11:109–31
   PubMed Web of Science ®Google Scholar
• Jiang H, Sun J, Xu Q, et al. (2013). Marchantin M: A novel inhibitor of proteasome induces autophagic cell death in prostate cancer cells. Cell Death Dis 4:e761
   Google Scholar
• Jiang Q, Yeh S, Wang X, et al. (2012). Targeting androgen receptor leads to suppression of prostate cancer via induction of autophagy. J Urol 188:1361–8
   PubMed Web of Science ®Google Scholar
• Jiang SW, Eberhardt NL. (1995). A micro-scale method to isolate DNA-binding proteins suitable for quantitative comparison of expression levels from transfected cells. Nucleic Acids Res 23:3607–8
   PubMed Web of Science ®Google Scholar
• Johnson DG, Degregori J. (2006). Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med 6:731–8
   PubMed Web of Science ®Google Scholar
• Kar G, Keskin O, Fraternali F, Gursoy A. (2013). Emerging role of the ubiquitin-proteasome system as drug targets. Curr Pharm Des 19:3175–89
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Chinnakannu K, Chen D, et al. (2007). Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67:7782–8
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kanzawa T, Sawaya R, Kondo S. (2005). The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–34
   PubMed Web of Science ®Google Scholar
• Lin H, Altuwaijri S, Lin W, et al. (2002). Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 277:36570–6
   PubMed Web of Science ®Google Scholar
• Loidl G, Groll M, Musiol HJ, et al. (1999). Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA 96:5418–22
   PubMed Web of Science ®Google Scholar
• Lu Z, Fan P, Ji M, Lou H. (2006). Terpenoids and bisbibenzyls from Chinese liverworts Conocephalum conicum and Dumortiera hirsuta. J Asian Nat Prod Res 8:187–92
   PubMed Web of Science ®Google Scholar
• Micel LN, Tentler JJ, Smith PG, Eckhardt GS. (2013). Role of ubiquitin ligases and the proteasome in oncogenesis: Novel targets for anticancer therapies. J Clin Oncol 31:1231–8
   PubMed Web of Science ®Google Scholar
• Mori A, Lehmann S, O'Kelly J, et al. (2006). Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res 66:3222–9
   PubMed Web of Science ®Google Scholar
• Nam S, Smith D, Dou Q. (2001). Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276:13322–30
   PubMed Web of Science ®Google Scholar
• Qu J, Xie C, Guo H, et al. (2007). Antifungal dibenzofuran bis(bibenzyl)s from the liverwort Asterella angusta. Phytochemistry 68:1767–74
   PubMed Web of Science ®Google Scholar
• Reddy G, Barrack E, Dou Q, et al. (2006). Regulatory processes affecting androgen receptor expression, stability, and function: Potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98:1408–23
   PubMed Web of Science ®Google Scholar
• Seruga B, Ocana A, Tannock IF. (2011). Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8:12–23
   PubMed Web of Science ®Google Scholar
• Sheflin L, Keegan B, Zhang W, Spaulding S. (2000). Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276:144–50
   PubMed Web of Science ®Google Scholar
• Shi Y, Liao Y, Qu X, et al. (2008). Marchantin C, a macrocyclic bisbibenzyl, induces apoptosis of human glioma A172 cells. Cancer Lett 262:173–82
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhu C, Yuan H, et al. (2009). Marchantin C, a novel microtubule inhibitor from liverwort with anti-tumor activity both in vivo and in vitro. Cancer Lett 276:160–70
   PubMed Web of Science ®Google Scholar
• Xu A, Hu Z, Qu J, et al. (2010). Cyclic bisbibenzyls induce growth arrest and apoptosis of human prostate cancer PC3 cells. Acta Pharmacol Sin 31:609–15
   PubMed Web of Science ®Google Scholar
• Xue X, Qu X, Gao Z, et al. (2012). Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II. Invest New Drugs 30:212–22
   PubMed Web of Science ®Google Scholar
• Yang H, Shi G, Dou Q. (2007). The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from “Indian winter cherry”. Mol Pharmacol 71:426–37
   PubMed Web of Science ®Google Scholar
• Yeap B, Voon D, Vivian J, et al. (2002). Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3′-untranslated region of the androgen receptor messenger RNA. J Biol Chem 277:27183–92
   PubMed Web of Science ®Google Scholar
• Yuan H, Kong F, Wang X, et al. (2008). Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol 75:2112–21
   PubMed Web of Science ®Google Scholar
• Zhu K, Dunner K-Jr, McConkey D. (2010). Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 29:451–62
   PubMed Web of Science ®Google Scholar
• Zhu M, Kyprianou N. (2008). Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 15:841–9
   PubMed Web of Science ®Google Scholar